[1]
|
Kostic, J., Djordjevic-Dikic, A., Dobric, M., Milasinovic, D., Nedeljkovic, M., Stojkovic, S., Stepanovic, J., Tesic, M., Trifunovic, Z., Zamaklar-Tifunovic, D., Radosavljevic-Radovanovic, M., Ostojic, M. and Beleslin, B. (2015) The Effects of Nicorandil on Microvascular Function in Patients with ST Segment Elevation Myocardial Infarction Undergoing Pri-mary PCI. Cardiovascular Ultrasound, 13, Article No 26. https://doi.org/10.1186/s12947-015-0020-9
|
[2]
|
Hirohata, A., Yamamoto, K., Hirose, E., Kobayashi, Y., Takafuji, H., Sano, F., Matsumoto, K., Ohara, M., Yoshioka, R., Takinami, H. and Ohe, T. (2014) Nicorandil Prevents Microvas-cular Dysfunction Resulting from PCI in Patients with Stable Angina Pectoris: A Randomised Study. EuroIntervention, 9, 1050-1056.
https://doi.org/10.4244/EIJV9I9A178
|
[3]
|
Shimokawa, H., Sunamura, S. and Satoh, K. (2016) RhoA/Rho-Kinase in the Cardiovascular System. Circulation Research, 118, 352-366. https://doi.org/10.1161/CIRCRESAHA.115.306532
|
[4]
|
Masumoto, A., Mohri, M., Shimokawa, H., Urakami, L., Usui, M. and Takeshita, A. (2002) Suppression of Coronary Artery Spasm by the Rho-Kinase Inhibitor Fasudil in Pa-tients with Vasospastic Angina. Circulation, 105, 1545-1547.
https://doi.org/10.1161/hc1002.105938
|
[5]
|
Suda, A., Takahashi, J., Hao, K., Kikuchi, Y., Shindo, T., Ikeda, S., Sato, K., Sugisawa, J., Matsumoto, Y., Miyata, S., Sakata, Y. and Shimokawa, H. (2019) Coronary Functional Abnor-malities in Patients with Angina and Nonobstructive Coronary Artery Disease. Journal of the American College of Car-diology, 74, 2350-2360.
https://doi.org/10.1016/j.jacc.2019.08.1056
|
[6]
|
Satoh, K., Fukumoto, Y. and Shimokawa, H. (2011) Rho-Kinase: Important New Therapeutic Target in Cardiovascular Diseases. American Journal of Physiology - Heart and Circulatory Physiology, 301, H287-H296.
https://doi.org/10.1152/ajpheart.00327.2011
|
[7]
|
Nihei, T., Takahashi, J., Hao, K., Kikuchi, Y., Odaka, Y., Tsuburaya, R., Nishimiya, K., Matsumoto, Y., Ito, K., Miyata, S., Sakata, Y. and Shimokawa, H. (2018) Prognostic Im-pacts of Rho-Kinase Activity in Circulating Leucocytes in Patients with Vasospastic Angina. European Heart Journal, 39, 952-959. https://doi.org/10.1093/eurheartj/ehx657
|
[8]
|
Neglia, D., Fommei, E., Varela-Carver, A., Mancini, M., Ghione, S., Lombardi, M., Pisani, P., Parker, H., D’Amati, G., Donato, L. and Camici, P.G. (2011) Perindopril and In-dapamide Reverse Coronary Microvascular Remodelling and Improve Flow in Arterial Hypertension. Journal of Hyper-tension, 29, 364-372.
https://doi.org/10.1097/HJH.0b013e328340a08e
|
[9]
|
Pauly, D.F., Johnson, B.D., Anderson, R.D., Handberg, E.M., Smith, K.M., Cooper-DeHoff, R.M., Sopko, G., Sharaf, B.M., Kelsey, S.F., Merz, C.N. and Pepine, C.J. (2011) In Women with Symptoms of Cardiac Ischemia, Nonobstructive Coronary Arteries, and Microvascular Dysfunction, Angiotensin-Converting Enzyme Inhibition Is Associated with Improved Microvascular Function: A Double-Blind Ran-domized Study from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE). American Heart Journal, 162, 678-684.
https://doi.org/10.1016/j.ahj.2011.07.011
|
[10]
|
Masuda, D., Nohara, R., Tamaki, N., Hosokawa, R., Inada, H., Hikai, T., Chen, L.G., Tadamura, E., Kudou, T., Konishi, J., Fujita, M. and Sasayama, S. (2000) Evaluation of Coronary Blood Flow Reserve by 13N-NH3 Positron Emission Computed Tomography (PET) with Dipyridamole in the Treatment of Hypertension with the ACE Inhibitor (Cilazapril). Annals of Nuclear Medicine, 14, 353-360. https://doi.org/10.1007/BF02988695
|
[11]
|
Higuchi, T., Abletshauser, C., Nekolla, S.G., Schwaiger, M. and Bengel, F.M. (2007) Effect of the Angiotensin Receptor Blocker Valsartan on Coronary Microvascular Flow Reserve in Moder-ately Hypertensive Patients with Stable Coronary Artery Disease. Microcirculation, 14, 805-812. https://doi.org/10.1080/10739680701410827
|
[12]
|
Kawata, T., Daimon, M., Hasegawa, R., Teramoto, K., Toyoda, T., Sekine, T., Yamamoto, K., Uchida, D., Himi, T., Yoshida, K. and Komuro, I. (2006) Effect on Coronary Flow Veloc-ity Reserve in Patients with Type 2 Diabetes Mellitus: Comparison between Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Type 1 Receptor Antagonist. American Heart Journal, 151, 798.e9-798.e15. https://doi.org/10.1016/j.ahj.2005.09.014
|
[13]
|
Akinboboye, O.O., Chou, R.L. and Bergmann, S.R. (2002) Aug-mentation of Myocardial Blood Flow in Hypertensive Heart Disease by Angiotensin Antagonists: A Comparison of Lis-inopril and Losartan. Journal of the American College of Cardiology, 40, 703-709. https://doi.org/10.1016/S0735-1097(02)02033-8
|
[14]
|
Sütsch, G., Oechslin, E., Mayer, I. and Hess, O.M. (1995) Effect of Diltiazem on Coronary Flow Reserve in Patients with Microvascular Angina. International Journal of Cardiol-ogy, 52, 135-143.
https://doi.org/10.1016/0167-5273(95)02458-9
|
[15]
|
Nishigaki, K., Inoue, Y., Yamanouchi, Y., Fukumoto, Y., Yasuda, S., Sueda, S., Urata, H., Shimokawa, H. and Minatoguchi, S. (2010) Prognostic Effects of Calcium Channel Blockers in Patients with Vasospastic Angina—A Meta-Analysis. Circulation Journal, 74, 1943-1950. https://doi.org/10.1253/circj.CJ-10-0292
|
[16]
|
Fukumoto, Y., Yasuda, S., Ito, A. and Shimokawa, H. (2008) Prog-nostic Effects of Benidipine in Patients with Vasospastic Angina: Comparison with Diltiazem and Amlodipine. Journal of Cardiovascular Pharmacology, 51, 253-257.
https://doi.org/10.1097/FJC.0b013e3181624b05
|
[17]
|
Mehta, P.K., Goykhman, P., Thomson, L.E., Shufelt, C., Wei, J., Yang, Y., Gill, E., Minissian, M., Shaw, L.J., Slomka, P.J., Slivka, M., Berman, D.S. and Bairey, M.C.N. (2011) Ranolazine Improves Angina in Women with Evidence of Myocardial Ischemia but No Obstructive Coronary Artery Disease. JACC: Cardiovascular Imagingg, 4, 514-522.
https://doi.org/10.1016/j.jcmg.2011.03.007
|
[18]
|
Rambarat, C.A., Elgendy, I.Y., Handberg, E.M., Bairey, M.C.N., Wei, J., Minissian, M.B., Nelson, M.D., Thomson, L.E.J., Berman, D.S., Shaw, L.J., Cook-Wiens, G. and Pepine, C.J. (2019) Late Sodium Channel Blockade Improves Angina and Myocardial Perfusion in Patients with Severe Coronary Microvascular Dysfunction: Women’s Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction Ancillary Study. International Journal of Cardiology, 276, 8-13.
https://doi.org/10.1016/j.ijcard.2018.09.081
|
[19]
|
Bairey, M.C.N., Handberg, E.M., Shufelt, C.L., Mehta, P.K., Minissian, M.B., Wei, J., Thomson, L.E., Berman, D.S., Shaw, L.J., Petersen, J.W., Brown, G.H., Anderson, R.D., Shuster, J.J., Cook-Wiens, G., Rogatko, A. and Pepine, C.J. (2016) A Randomized, Placebo-Controlled Trial of Late Na Current Inhibition (Ranolazine) in Coronary Microvascular Dysfunction (CMD): Impact on Angina and Myocardial Per-fusion Reserve. European Heart Journal, 37, 1504-1513.
https://doi.org/10.1093/eurheartj/ehv647
|
[20]
|
Shah, N.R., Cheezum, M.K., Veeranna, V., Horgan, S.J., Taqueti, V.R., Murthy, V.L., Foster, C., Hainer, J., Daniels, K.M., Rivero, J., Shah, A.M., Stone, P.H., Morrow, D.A., Steigner, M.L., Dorbala, S., Blankstein, R. and Di Carl, M.F.I. (2017) Ranolazine in Symptomatic Diabetic Patients without Ob-structive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. Journal of the American Heart As-sociation, 6, Article ID: e005027.
https://doi.org/10.1161/JAHA.116.005027
|
[21]
|
Koh, J.S., Hung, O.Y., Eshtehardi, P., Kumar, A., Rabah, R., Raad, M., Kumar, S., Chaudhry, S., Gupta, S., Hosseini, H., Brilakis, E., Corban, M., Sabbak, N., Burnett, G.M., Liu, C., Me-hta, P.K., Quyyumi, A.A. and Samady, H. (2020) Microvascular Assessment of Ranolazine in Non-Obstructive Athero-sclerosis: The MARINA Randomized, Double- Blinded, Controlled Pilot Trial. Circulation: Cardiovascular Interven-tions, 13, Article ID: e008204.
https://doi.org/10.1161/CIRCINTERVENTIONS.119.008204
|
[22]
|
Rogacka, D., Guzik, P., Wykretowicz, A., Rzeźniczak, J., Dziarmaga, M. and Wysocki, H. (2000) Effects of Trimetazidine on Clinical Symptoms and Tolerance of Exercise of Patients with Syndrome X: A Preliminary Study. Coronary Artery Disease, 11, 171-177. https://doi.org/10.1097/00019501-200003000-00012
|
[23]
|
Chiang, C.Y., Chien, C.Y., Qiou, W.Y., Chang, C., Yu, I.S., Chang, P.Y. and Chien, C.T. (2018) Genetic Depletion of Thromboxane A2/Thromboxane-Prostanoid Receptor Signalling Prevents Microvascular Dysfunction in Ischaemia/ Reperfusion Injury. Thrombosis and Haemostasis, 118, 1982-1996. https://doi.org/10.1055/s-0038-1672206
|
[24]
|
Park, K., Cho, Y.R., Park, J.S., Park, T.H., Kim, M.H. and Kim, Y.D. (2019) Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients with Acute Coronary Syndrome Using Invasive Physiologic Indices. Circulation: Cardiovascular Interventions, 12, Ar-ticle ID: e008105.
https://doi.org/10.1161/CIRCINTERVENTIONS.119.008105
|
[25]
|
Scanavini-Filho, M.A., Berwanger, O., Mat-thias, W., Aguiar, M.O., Chiang, H.P., Azevedo, L., Baracioli, L.M., Lima, F.G., Furtado, R.H.M., Dalcoquio, T.F., Menezes, F.R., Ferrari, A.G., De Luca, F., Giugliano, R.P., Goodman, S. and Nicolau, J.C. (2022) Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. Advances in Therapy, 39, 1832-1843. https://doi.org/10.1007/s12325-022-02061-0
|
[26]
|
Kayikcioglu, M., Payzin, S., Yavuzgil, O., Kultursay, H., Can, L.H. and Soydan, I. (2003) Benefits of Statin Treatment in Cardiac Syndrome-X1. European Heart Journal, 24, 1999-2005. https://doi.org/10.1016/S0195-668X(03)00478-0
|
[27]
|
Caliskan, M., Erdogan, D., Gullu, H., Topcu, S., Ciftci, O., Yildirir, A. and Muderrisoglu, H. (2007) Effects of Atorvastatin on Coronary Flow Reserve in Patients with Slow Coronary Flow. Clinical Cardiology, 30, 475-479.
https://doi.org/10.1002/clc.20140
|
[28]
|
Quyyumi, A.A., Dakak, N., Andrews, N.P., Gilligan, D.M., Panza, J.A. and Cannon III, R.O. (1995) Contribution of Nitric Oxide to Metabolic Coronary Vasodilation in the Human Heart. Circula-tion, 92, 320-326.
https://doi.org/10.1161/01.CIR.92.3.320
|
[29]
|
Togni, M., Vigorito, F., Windecker, S., Abrecht, L., Wenaweser, P., Cook, S., Billinger, M., Meier, B. and Hess, O.M. (2007) Does the Beta-Blocker Nebivolol Increase Coronary Flow Reserve? Cardiovascular Drugs and Therapy, 21, 99-108. https://doi.org/10.1007/s10557-006-0494-7
|
[30]
|
Galderisi, M. and D’Errico, A. (2008) Beta-Blockers and Coro-nary Flow Reserve: The Importance of a Vasodilatory Action. Drugs, 68, 579-590. https://doi.org/10.2165/00003495-200868050-00002
|
[31]
|
Borer, J.S., Fox, K., Jaillon, P. and Lerebours, G. (2003) Antianginal and Antiischemic Effects of Ivabradine, an I(f) Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial. Circulation, 107, 817-823. https://doi.org/10.1161/01.CIR.0000048143.25023.87
|
[32]
|
Skalidis, E.I., Hamilos, M.I., Chlouverakis, G., Zacha-ris, E.A. and Vardas, P.E. (2011) Ivabradine Improves Coronary Flow Reserve in Patients with Stable Coronary Artery Disease. Atherosclerosis, 215, 160-165.
https://doi.org/10.1016/j.atherosclerosis.2010.11.035
|
[33]
|
Egashira, K., Hirooka, Y., Kuga, T., Mohri, M. and Takeshita, A. (1996) Effects of L-Arginine Supplementation on Endothelium-Dependent Coronary Vasodilation in Pa-tients with Angina Pectoris and Normal Coronary Arteriograms. Circulation, 94, 130-134. https://doi.org/10.1161/01.CIR.94.2.130
|
[34]
|
Lerman, A., Burnett Jr., J.C., Higano, S.T., McKinley, L.J. and Holmes Jr., D.R. (1998) Long-Term L-Arginine Supplementation Improves Small-Vessel Coronary Endothelial Function in Humans. Circulation, 97, 2123-2128.
https://doi.org/10.1161/01.CIR.97.21.2123
|
[35]
|
Najjar, R.S., Schwartz, A.M., Wong, B.J., Mehta, P.K. and Feresin, R.G. (2021) Berries and Their Polyphenols as a Potential Therapy for Coronary Microvascular Dysfunction: A Mini-Review. International Journal of Molecular Sciences, 22, Article No. 3373. https://doi.org/10.3390/ijms22073373
|
[36]
|
Xuan, C., Tian, Q.W., Li, H., Zhang, B.B., He, G.W. and Lun, L.M. (2016) Levels of Asymmetric Dimethylarginine (ADMA), an Endogenous Nitric Oxide Synthase Inhibitor, and Risk of Coronary Artery Disease: A Meta-Analysis Based on 4713 Participants. European Journal of Preventive Cardiolog, 23, 502-510.
https://doi.org/10.1177/2047487315586094
|
[37]
|
Suda, O., Tsutsui, M., Morishita, T., Tasaki, H., Ueno, S., Nakata, S., Tsujimoto, T., Toyohira, Y., Hayashida, Y., Sasaguri, Y., Ueta, Y., Nakashima, Y. and Yanagihara, N. (2004) Asymmetric Dimethylarginine Produces Vascular Lesions in Endothelial Nitric Oxide Synthase-Deficient Mice: In-volvement of Renin-Angiotensin System and Oxidative Stress. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1682-1688.
https://doi.org/10.1161/01.ATV.0000136656.26019.6e
|
[38]
|
Verhaar, M.C., Strachan, F.E., Newby, D.E., Cruden, N.L., Koomans, H.A., Rabelink, T.J. and Webb, D.J. (1998) Endothelin-A Receptor Antagonist-Mediated Vasodilatation Is Attenuated by Inhibition of Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade. Circulation, 97, 752-756. https://doi.org/10.1161/01.CIR.97.8.752
|
[39]
|
Ford, T.J., Rocchiccioli, P., Good, R., McEntegart, M., Eteiba, H., Watkins, S., Shaukat, A., Lindsay, M., Robertson, K., Hood, S., Yii, E., Sidik, N., Harvey, A., Montezano, A.C., Beattie, E., Haddow, L., Oldroyd, K.G., Touyz, R.M. and Berry, C. (2018) Systemic Microvascular Dysfunction in Microvascu-lar and Vasospastic Angina. European Heart Journal, 39, 4086-4097. https://doi.org/10.1093/eurheartj/ehy529
|
[40]
|
Naya, M., Aikawa, T., Manabe, O., Obara, M., Koyanagawa, K., Katoh, C. and Tamaki, N. (2021) Elevated Serum Endothelin-1 Is an Independent Predictor of Coronary Microvascular Dysfunction in Non-Obstructive Territories in Patients with Coronary Artery Disease. Heart and Vessels, 36, 917-923. https://doi.org/10.1007/s00380-020-01767-x
|
[41]
|
Kaski, J.C., Elliott, P.M., Salomone, O., Dickinson, K., Gordon, D., Hann, C. and Holt, D.W. (1995) Concentration of Circulating Plasma Endothelin in Patients with Angina and Normal Coronary Angiograms. Heart, 74, 620-624.
https://doi.org/10.1136/hrt.74.6.620
|
[42]
|
Yoon, M.H., Reriani, M., Mario, G., Rihal, C., Gulati, R., Lennon, R., Tilford, J.M., Lerman, L.O. and Lerman, A. (2013) Long-Term Endothelin Receptor Antagonism Attenuates Coronary Plaque Progression in Patients with Early Atherosclerosis. International Journal of Cardiology, 168, 1316-1321. https://doi.org/10.1016/j.ijcard.2012.12.001
|
[43]
|
Reriani, M., Raichlin, E., Prasad, A., Mathew, V., Pumper, G.M., Nelson, R.E., Lennon, R., Rihal, C., Lerman, L.O. and Lerman, A. (2010) Long-Term Administration of Endothelin Re-ceptor Antagonist Improves Coronary Endothelial Function in Patients with Early Atherosclerosis. Circulation, 122, 958-966.
https://doi.org/10.1161/CIRCULATIONAHA.110.967406
|
[44]
|
Halcox, J.P., Nour, K.R., Zalos, G. and Quyyumi, A.A. (2001) Coronary Vasodilation and Improvement in Endothelial Dysfunction with Endothelin ET(A) Receptor Blockade. Circulation Research, 89, 969-976.
https://doi.org/10.1161/hh2301.100980
|
[45]
|
Tawakol, A., Forgione, M.A., Stuehlinger, M., Alpert, N.M., Cooke, J.P., Loscalzo, J., Fischman, A.J., Creager, M.A. and Gewirtz, H. (2002) Homocysteine Impairs Coronary Microvascu-lar Dilator Function in Humans. Journal of the American College of Cardiology, 40, 1051-1058. https://doi.org/10.1016/S0735-1097(02)02069-7
|
[46]
|
Bleie, Ø., Strand, E., Ueland, P.M., Vollset, S.E., Refsum, H., Igland, J., Nordrehaug, J.E. and Nygård, O.K. (2011) Coronary Blood Flow in Patients with Stable Coronary Artery Disease Treated Long Term with Folic Acid and Vitamin B12. Coronary Artery Disease, 22, 270-278. https://doi.org/10.1097/MCA.0b013e328344fff4
|
[47]
|
Tawakol, A., Migrino, R.Q., Aziz, K.S., Waitkowska, J., Holmvang, G., Alpert, N.M., Muller, J.E., Fischman, A.J. and Gewirtz, H. (2005) High-Dose Folic Acid Acutely Im-proves Coronary Vasodilator Function in Patients with Coronary Artery Disease. Journal of the American College of Cardiology, 45, 1580-1584.
https://doi.org/10.1016/j.jacc.2005.02.038
|
[48]
|
Watanabe, K., Ikeda, S., Komatsu, J., Inaba, S., Suzuki, J., Sueda, S., Funada, J., Kitakaze, M. and Sekiya, M. (2003) Effect of Cilostazol on Vasomotor Reactivity in Patients with Vaso-spastic Angina Pectoris. American Journal of Cardiology, 92, 21-25. https://doi.org/10.1016/S0002-9149(03)00458-2
|
[49]
|
Shin, E.S., Lee, J.H., Yoo, S.Y., Park, Y., Hong, Y.J., Kim, M.H., Lee, J.Y., Nam, C.W., Tahk, S.J., Kim, J.S., Jeong, Y.H., Lee, C.W., Shin, H.K. and Kim, J.H. (2014) A Ran-domised, Multicentre, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Cilostazol in Patients with Vasospastic Angina. Heart, 100, 1531-1536.
https://doi.org/10.1136/heartjnl-2014-305986
|
[50]
|
Halcox, J.P., Nour, K.R., Zalos, G., Mincemoyer, R.A., Waclawiw, M., Rivera, C.E., Willie, G., Ellahham, S. and Quyyumi, A.A. (2002) The Effect of Sildenafil on Human Vascular Function, Platelet Activation, and Myocardial Ischemia. Journal of the American College of Cardiology, 40, 1232-1240.
https://doi.org/10.1016/S0735-1097(02)02139-3
|
[51]
|
Traverse, J.H., Chen, Y.J., Du, R. and Bache, R.J. (2000) Cyclic Nucleotide Phosphodiesterase Type 5 Activity Limits Blood Flow to Hypoperfused Myocardium During Exercise. Circulation, 102, 2997-3002.
https://doi.org/10.1161/01.CIR.102.24.2997
|
[52]
|
Robinson, S.D., Ludlam, C.A., Boon, N.A. and Newby, D.E. (2006) Phosphodiesterase Type 5 Inhibition Does Not Reverse Endothelial Dysfunction in Patients with Coronary Heart Disease. Heart, 92, 170-176.
https://doi.org/10.1136/hrt.2004.059683
|
[53]
|
Henry, T.D., Bairey, M.C.N., Wei, J., Corban, M.T., Quesada, O., Joung, S., Kotynski, C.L., Wang, J., Lewis, M., Schumacher, A.M., Bartel, R.L., Takagi, H., Shah, V., Lee, A., Sietsema, W.K., Losordo, D.W. and Lerman, A. (2022) Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients with Coronary Microvascular Dysfunction. Circulation: Cardiovascular Interventions, 15, Article ID: e010802.
https://doi.org/10.1161/CIRCINTERVENTIONS.121.010802
|
[54]
|
Corban, M.T., Toya, T., Albers, D., Sebaali, F., Lewis, B.R., Bois, J., Gulati, R., Prasad, A., Best, P.J.M., Bell, M.R., Rihal, C.S., Prasad, M., Ahmad, A., Lerman, L.O., Solseth, M.L., Winters, J.L., Dietz, A.B. and Lerman, A. (2022) IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients with Angina and Nonobstructive Coronary Arteries. Circulation Research, 130, 326-338.
https://doi.org/10.1161/CIRCRESAHA.121.319644
|
[55]
|
Jadhav, S., Ferrell, W., Greer, I.A., Petrie, J.R., Cobbe, S.M. and Sattar, N. (2006) Effects of Metformin on Microvascular Function and Exercise Tolerance in Women with An-gina and Normal Coronary Arteries: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of the American College of Cardiology, 48, 956-963.
https://doi.org/10.1016/j.jacc.2006.04.088
|
[56]
|
Merz, C.N., Olson, M.B., McClure, C., Yang, Y.C., Symons, J., Sopko, G., Kelsey, S.F., Handberg, E., Johnson, B.D., Cooper-DeHoff, R.M., Sharaf, B., Rogers, W.J. and Pepine, C.J. (2010) A Randomized Controlled Trial of Low-Dose Hormone Therapy on Myocardial Ischemia in Postmenopausal Women with No Obstructive Coronary Artery Disease: Results from the National Institutes of Health/National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). American Heart Journal, 159, 987.e1-987.e7. https://doi.org/10.1016/j.ahj.2010.03.024
|
[57]
|
Pedersen, L.R., Olsen, R.H., Anholm, C., Astrup, A., Eugen-Olsen, J., Fenger, M., Simonsen, L., Walzem, R.L., Haugaard, S.B. and Prescott, E. (2019) Effects of 1 Year of Exercise Training Versus Combined Exercise Training and Weight Loss on Body Composition, Low-Grade Inflamma-tion and Lipids in Overweight Patients with Coronary Artery Disease: A Randomized Trial. Cardiovascular Diabetology, 18, Article No. 127.
https://doi.org/10.1186/s12933-019-0934-x
|
[58]
|
Olsen, R.H., Pedersen, L.R., Jürs, A., Snoer, M., Haugaard, S.B. and Prescott, E. (2015) A Randomised Trial Comparing the Effect of Exercise Training and Weight Loss on Microvascu-lar Function in Coronary Artery Disease. International Journal of Cardiology, 185, 229-235. https://doi.org/10.1016/j.ijcard.2015.03.118
|
[59]
|
Eriksson, B.E., Tyni-Lennè, R., Svedenhag, J., Hallin, R., Jen-sen-Urstad, K., Jensen-Urstad, M., Bergman, K. and Selvén, C. (2000) Physical Training in Syndrome X: Physical Training Counteracts Deconditioning and Pain in Syndrome X. ournal of the American College of Cardiology, 36, 1619-1625.
https://doi.org/10.1016/S0735-1097(00)00931-1
|
[60]
|
Tyni-Lenne, R., Stryjan, S., Eriksson, B., Berglund, M. and Sylven, C. (2002) Beneficial Therapeutic Effects of Physical Training and Relaxation Therapy in Women with Coronary Syndrome X. Physiotherapy Research International, 7, 35-43. https://doi.org/10.1002/pri.239
|
[61]
|
Sgueglia, G.A., Sestito, A., Spinelli, A., Cioni, B., Infusino, F., Papacci, F., Bellocci, F., Meglio, M., Crea, F. and Lanza, G.A. (2007) Long-Term Follow-Up of Patients with Cardiac Syndrome X Treated by Spinal Cord Stimulation. Heart, 93, 591-597. https://doi.org/10.1136/hrt.2006.102194
|
[62]
|
Lanza, G.A., Sestito, A., Sgueglia, G.A., Infusino, F., Papacci, F., Visocchi, M., Ierardi, C., Meglio, M., Bellocci, F. and Crea, F. (2005) Effect of Spinal Cord Stimulation on Spontaneous and Stress-Induced Angina and ‘Ischemia-Like’ ST-Segment Depression in Patients with Cardiac Syndrome X. Europe-an Heart Journal, 26, 983-989.
https://doi.org/10.1093/eurheartj/ehi089
|
[63]
|
Kronhaus, K.D. and Lawson, W.E. (2009) Enhanced External Coun-terpulsation Is an Effective Treatment for Syndrome X. International Journal of Cardiology, 135, 256-257. https://doi.org/10.1016/j.ijcard.2008.03.022
|
[64]
|
Loh, P.H., Louis, A.A., Windram, J., Rigby, A.S., Cook, J., Hur-ren, S., Nikolay, N.P., Caplin, J. and Cleland, J.G. (2006) The Immediate and Long-Term Outcome of Enhanced External Counterpulsation in Treatment of Chronic Stable Refractory Angina. Journal of Internal Medicine, 259, 276-284. https://doi.org/10.1111/j.1365-2796.2005.01604.x
|